Printer Friendly

SCICLONE PHARMACEUTICALS INC. INITIAL PUBLIC OFFERING

 SCICLONE PHARMACEUTICALS INC. INITIAL PUBLIC OFFERING
 SAN MATEO, Calif., March 17 /PRNewswire/ -- SciClone Pharmaceuticals Inc. today announced the initial public offering of 3,000,000 shares of common stock, and 3,000,000 redeemable warrants, at prices of $7.25 and $0.20 respectively.
 The common stock and the redeemable warrants will both trade on the NASDAQ National Market System under the symbols SCLN for the common stock, and SCLNW for the redeemable warrants.
 The offering was made by a syndicate of underwriters led by Josephthal Lyon & Ross Inc., New York.
 The company has granted to the underwriters an option to purchase up to 450,000 additional shares and up to 450,000 additional warrants from the company for the purpose of covering over-allotments, if any.
 SciClone Pharmaceuticals Inc. is primarily engaged in the acquisition and development of pharmaceuticals which it intends to market on a worldwide basis.
 This announcement is neither an offer to sell nor a solicitation of an offer to buy the company's securities. The offering is made only by the prospectus, copies of which are available from Josephthal Lyon & Ross.
 -0- 3/17/92
 /CONTACT: Tom Moore or Nelson Schneider, both of SciClone Pharmaceuticals, 415-358-3456/
 (SCLN) CO: SciClone Pharmaceuticals ST: California IN: MTC SU: OFR


RM -- SF009 -- 8873 03/17/92 15:50 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 17, 1992
Words:218
Previous Article:YOUNG ELECTED CHAIRMAN AT HI-LO AUTOMOTIVE, INC.
Next Article:OMNICORP SELLS SUBSIDIARIES ENGAGED IN FREIGHT FORWARDING AND REMAILING
Topics:


Related Articles
SCICLONE PHARMACEUTICALS ANNOUNCES CLINICAL DEVELOPMENT/COMMERCIALIZATION AGREEMENT WITH SCHERING-PLOUGH K.K.
SCICLONE PHARMACEUTICALS ANNOUNCES APPROVAL TO BEGIN CLINICAL TRIALS IN JAPAN FOR THYMOSIN ALPHA 1
SCICLONE PHARMACEUTICALS, INC. COMPLETES PUBLIC OFFERING OF COMMON STOCK
SCICLONE ACQUIRES STAKE IN ALPHA 1
SCICLONE'S BOARD APPROVES STOCK BUYBACK
SCICLONE EXPANDS STOCK BUYBACK PROGRAM TO 1.5 MILLION SHARES
SCICLONE'S BOARD APPROVES STOCK BUYBACK
SCICLONE PHARMACEUTICALS ACQUIRES LICENSE FOR CYSTIC FIBROSIS DRUG FROM THE NATIONAL INSTITUTES OF HEALTH
Meyers-Pollock-Robbins, Inc. Upgrades SciClone Pharmaceuticals To a Strong Buy Recommendation
SciClone Pharmaceuticals Responds to Recent Shareholder Inquiries

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters